According to FutureWise analysis the market for intravitreal (ivt) injectables in 2023 was US$ 15.7 billion, and is expected to reach US$ 27 billion by 2031 at a CAGR of 6.5%.
Intravitreal injection is the process of injecting drugs into the eyeball using a fine needle. These medications will then be administered directly to the vitreous humour. This medication can treat some eye diseases, including age-related macular degeneration (AMD), diabetic retinopathy, and infections inside the eye, such as endophthalmitis. When compared to topical administration, this method allows for more targeted medication delivery because the needle can pass directly through the anatomical (e.g., cornea, conjunctiva, and lens) and dynamic barriers (e.g., tears and aqueous humour). It may also reduce adverse drug effects to other body tissues via systemic circulation, which may be a risk with intravenous medication injection.
Wet age-related macular degeneration (AMD) causes vision loss because new, aberrant, leaky blood vessels begin to invade the retina, filling it with extra fluid and causing it to enlarge. A molecule known as VEGF, or vascular endothelial growth factor, is one of the key initiators of this blood vessel expansion. Many medications that prevent the activity of VEGF have been created over the past 15 years, lowering swelling, at least partially recovering eyesight, or maintaining the course of the disease. Anti-VEGF medications must be injected into the eye because they are big molecules and cannot be taken orally or used as eyedrops to achieve the desired effects. Intravitreal (IVT) injections are used to provide the medication because they are injected into the vitreous, which is located in front of the retina.
According to the research study conducted by FutureWise research analysts, the Intravitreal (IVT) Injectables Market is anticipated to attain substantial growth by the end of the forecast period.
Request a Free Sample @ https://www.futurewiseresearch.com/healthcare-market-research/Intravitreal-(IVT)-Injectables/259
Intravitreal (IVT) Injectables Market Segmentation:
By Drug Class
- Anti-VEGF
- Antibiotics
- Corticosteroids
- Antifungals
- Antivirals
By Indication
- Diabetic Retinopathy
- Macular Degeneration
- Endophthalmitis
- Retinal Vein Occlusions
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Competitive Landscape in the Intravitreal (IVT) Injectables Market:
- Alcon Pharmaceuticals
- Novartis
- Regeneron Pharmaceuticals Inc.
- Allergan
- Alimera Sciences
- Bristol Myers Squibb
- Bausch And Lomb
- F. Hoffmann-La Roche
- Thrombogenics
- Valeant Pharmaceuticals International
Buy now the latest version of this report:
https://www.futurewiseresearch.com/contact.aspx?rpt=259%20&type=discount
**Objectives of this Study: **
- To provide a comprehensive analysis of the Intravitreal (IVT) Injectables Market By Drug Class, By Indication, By Distribution Channel and By Region.
- To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
- To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
- To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Flexible Delivery Model:
- We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
- The customization services offered are free of charge with the purchase of any license of the report.
- You can directly share your requirements/changes to the current table of contents to: [email protected]
FutureWise Research
Contact Person: Vinay Thaploo.
Email: [email protected]
Contact Number: Asia: +91 8605575209 | USA: +1 3477094931
Website: www.futurewiseresearch.com